S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of
estrogen. It is not yet known whether anastrozole is more effective with or without
fulvestrant in treating breast cancer.
PURPOSE: This randomized phase III trial is studying giving anastrozole together with
fulvestrant to see how well it works compared to anastrozole alone as first-line therapy in
treating postmenopausal women with metastatic breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
National Cancer Institute (NCI) NCIC Clinical Trials Group